TYGRIS - ROW: TYSABRI® Global Observational Program in Safety - Rest of World
N/A
N/A
Both
Multiple Sclerosis
Trial Information
TYGRIS - ROW: TYSABRI® Global Observational Program in Safety - Rest of World
The TYSABRI® Global Observational Program in Safety for Rest of World (TYGRIS - ROW)is a
safety observational cohort program designed to obtain long-term safety data in MS patients
treated with TYSABRI® in a clinical practice setting in countries other than the United
States and Canada.
The Prescribing Physician will collect patient information at routine clinic visits (using
standard data collection tools) at approximately 6-month intervals for 5 years from the
first TYSABRI® infusion.
Inclusion Criteria:
- All MS patients in ROW who are prescribed and receiving TYSABRI® in normal clinical
practice at centers that are taking part in the study, are eligible to participate in
TYGRIS - ROW. Patients must have received at least 1 and not more than 3 infusions of
TYSABRI®.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
101MS403
NCT ID:
NCT00483847
Start Date:
September 2006
Completion Date:
June 2014
Related Keywords:
- Multiple Sclerosis
- TYSABRI
- TYGRIS - ROW
- natalizumab
- Multiple Sclerosis
- Multiple Sclerosis
- Sclerosis
Name | Location |
|---|
